Why we're excited about it
The clinicians current stock of antibiotics is being rendered obsolete. Antibiotic resistance means bacterial infections previously considered trivial now routinely pose a mortal threat to patients. With few novel therapeutic classes reaching FDA approval in the past two decades this balance is not set to change, and AMR related deaths are predicted to exceed 10 million per year by 2050.
What is the answer? Classical drug discovery pipelines are considered ‘dried-up’, however there is ample opportunity for reinvigoration using data driven convergent science.
Synthetic phage, microbiome engineering, and intelligent approaches to small molecule bioprospecting all show value as solutions to the AMR crisis. Whilst many perceive the ‘low hanging fruit’ to be picked, we say people are not looking in the right places.
Link to your LinkedIn / CV / web
I'm interested in...
joining a project in this area
pitching an opportunity in this area
investing in this area
other collaboration opportunities
Never submit passwords through Google Forms.
This content is neither created nor endorsed by Google.
Terms of Service